Cancer · 2020 · 25 citations · 25 references
PharmacyOncologyPharmacokineticsChemotherapyMedical OncologyPharmacokinetics Of Anticancer AgentsChemotherapy Toxicity In Older AdultsChemotherapy Toxicity ManagementPharmacodynamics Of Anticancer DrugsPharmacokinetics Of Anticancer DrugsSarcoma PharmacotherapyToxicity ManagementAnthracycline-based ChemotherapyChemotherapy PharmacodynamicsClinical Trials In SarcomaComparative Clinical TrialsElderly PopulationGeriatric Chemotherapy ToxicitySerious Adverse EventsSoft Tissue Sarcoma Treatment
Background Although elderly patients (≥70 years) represent 30% of new diagnoses of soft tissue sarcoma (STS), they are underrepresented in clinical trials and are often unfit to receive standard anthracycline‐based chemotherapy. Trabectedin is registered as a second‐line treatment for advanced STS and is characterized by a favorable safety profile. Methods The aim of this single‐arm, phase 2 study was to investigate trabectedin (scheduled dose, 1.3‐1.5 mg/m 2 ) as a first‐line treatment in elderly patients with advanced stage STS who are inoperable and are unfit to receive standard anthracycline‐based chemotherapy. The coprimary endpoints were progression‐free survival at 3 months (PFS3) and the rate of clinically limiting toxicities (CLTs). We also conducted an ancillary study on pharmacokinetics. Results Twenty‐four patients (12 men and 12 women) with a median age of 79 years (interquartile range [IQR], 74‐83 years) were enrolled. The histological subtype was leiomyosarcoma in 46%, liposarcoma in 33%, and other histotypes in 21%. The median number of trabectedin courses was 4 (IQR, 3‐6), with 7 patients (29%) receiving ≥6 cycles. Eight patients (33%) required dose reductions. The most frequent grade 3/4 adverse events were neutropenia in 9 patients (38%), fatigue in 5 patients (21%), and aminotransferase elevation in 5 patients (21%). PFS3, median PFS, and overall survival were 71% (80% CI, 57%‐81%), 4 months, and 12 months, respectively. Ten patients (42% [80% CI, 28%‐57%]) experienced CLTs. Trabectedin C max , half‐life, clearance, and distribution volume were 1.28 ng/mL (standard deviation [SD], 0.58 ng/mL), 26.70 hours (SD, 9.09 hours), 39.98 L/h/m 2 (SD, 14.08 L/h/m 2 ), and 1460 L/m 2 (SD, 561 L/m 2 ), respectively. Conclusion Trabectedin can be administered safely to elderly patients with STS who are unfit to receive anthracyclines. Pharmacokinetics in the elderly population was superimposable to historical data.
25
Ian Judson, Jaap Verweij, Hans Gelderblom et al. · The Lancet Oncology · 2014 · 1.2K citations · Full text
Medicine, Oncology, Pharmacology +13
George D. Demetri, Margaret von Mehren, Robin L. Jones et al. · Journal of Clinical Oncology · 2015 · 834 citations · Full text
Medicine, Oncology, Pharmacology +17
George D. Demetri, Sant P. Chawla, Margaret von Mehren et al. · Journal of Clinical Oncology · 2009 · 536 citations · Full text
Medicine, Oncology, Pharmacology +15